# EDGAR Filing Document

**Accession Number:** 0001625288
**File Stem:** 0001493152-25-014184
**Filing Date:** 2025-9
**Character Count:** 2991
**Document Hash:** 957ad09023e3e872b7165739c940594c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-014184.hdr.sgml**: 20250919

**ACCESSION NUMBER**: 0001493152-25-014184

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250919

**DATE AS OF CHANGE**: 20250919

**EFFECTIVENESS DATE**: 20250919

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEXIEN BIOPHARMA, INC.
- **CENTRAL INDEX KEY:** 0001625288
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262049376
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55320
- **FILM NUMBER:** 251325977

**BUSINESS ADDRESS:**
- **STREET 1:** 4340 E KENTUCKY AVE
- **STREET 2:** SUITE 206
- **CITY:** GLENDALE
- **STATE:** CO
- **ZIP:** 80246
- **BUSINESS PHONE:** 3034957583

**MAIL ADDRESS:**
- **STREET 1:** 4340 E KENTUCKY AVE
- **STREET 2:** SUITE 206
- **CITY:** GLENDALE
- **STATE:** CO
- **ZIP:** 80246

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Intiva BioPharma Inc.
- **DATE OF NAME CHANGE:** 20171129

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kinder Holding Corp.
- **DATE OF NAME CHANGE:** 20141114

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934.**

**Commission File No. 000-55320**

**Nexien BioPharma, Inc.**

(Exact name of registrant as specified in its charter)

**4340 East Kentucky Avenue, Suite 206**

**Glendale, Colorado 80246**

**(303) 495-7583** 

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Common Stock, par value $0.0001 per share**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | **☐** |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | **☐** |

---

Approximate number of holders of record as of the certification or notice date: 106.

Pursuant to the requirements of the Securities Exchange Act of 1934, GMS Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Dated: September 18, 2025 | **NEXIEN BIOPHARMA, INC.** | **NEXIEN BIOPHARMA, INC.** |
|  | By: | */s/ Richard Greenberg* |
|  | Name: | Richard Greenberg |
|  | Title: | Chief Executive Officer |

---